January 1, 2023Open Access

Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study

Key Points

Key points are not available for this paper at this time.

Abstract

ClinicalTrials.gov NCT04562766: https://clinicaltrials.gov/ct2/show/NCT04562766; EU Clinical Trials Register EudraCT 2020-002063-60: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002063-60.

KI fragen

Bookmark

View Full Paper

Cite This Study

Kuter et al. (Sun,) studied this question.

synapsesocial.com/papers/69d91c17da3af5b1d08359f2 https://doi.org/https://doi.org/10.1177/20406207231205431

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia2022 · 139 citations
2Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity2017 · 271 citations
3Prevalence of immune thrombocytopenia: analyses of administrative data2006 · 270 citations
4A disease-specific measure of health-related quality of life in adults with chronic Immune Thrombocytopenic Purpura: Psychometric testing in an open-label clinical trial2007 · 45 citations
5LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia2021 · 9 citations

KI fragen

Bookmark

View Full Paper